Biofeedback for Dysfunctional Voiding and Giggle Incontinence

Biofeedback for Dysfunctional Voiding and Giggle Incontinence in Children

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07268963

Enrollment

Registered

2025-12-08

Start date

2022-09-01

Completion date

2026-04-30

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biofeedback Therapy, Dysfunctional Voiding, Giggle Incontinence

Keywords

Giggle, Dysfunctional voiding, Incontinence, Biofeedback

Brief summary

This study aims to evaluate the efficacy of biofeedback treatment for dysfunctional voiding and giggle incontinence in children. Predictive factors of treatment success will also researched.

Detailed description

A total of approximately 60 patients who received biofeedback therapy will be evaluated retrospectively. Treatment success rates among these patients will be evaluated. Patients will be divided into mainly two groups according to the diagnosis.

Interventions

BEHAVIORALBiofeedback therapy

Biofeedback therapy is a behavioral treatment method that helps patients become more aware of and gain better control over their pelvic floor muscles. Using EMG electrodes, muscle activity is monitored and presented to the patient visually or audibly, enabling them to recognize and correct improper muscle contractions or relaxations that contribute to urinary incontinence.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

4 Years to 17 Years

Healthy volunteers

Inclusion criteria

* Patients diagnosed with dysfunctional voiding or giggle incontinence * Patients treated with biofeedback therapy

Exclusion criteria

* Presence of anatomical or neurological problems * Patients with missing data

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants with Biofeedback-Related Resolution	From enrollment to the end of treatment at 18 weeks	Participants achieved a complete response which means 100% improvement in resolution of incontinence and abnormal voiding pattern

Other

Measure	Time frame	Description
Predictive Factors of Treatment Response	18 weeks	Age, gender, and diagnosis will be evaluated as potential predictive factors of treatment response

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026